Related Experiment Video
Updated: Sep 30, 2026
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
Potentially therapeutically relevant differences of antisense oligonucleotide uptake in CD34+ hematopoietic stem
Abstract:
Antisense oligonucleotide (ON) technology, e.g. against drug resistance or antiapoptotic factors, may play an important role in future cancer chemotherapy. An unanswered question in this field is the capacity for uptake of antisense molecules in normal and malignant patients' cells. Therefore, we examined the cellular uptake of FITC-labeled phosphorothioate modified ONs in: i) cells from the T-lymphoblastoid cell line CCRF-CEM, ii) CD34+ hematopoietic progenitors from healthy donors, iii) blasts from ALL or AML patients, iv) cells from the ovarian cancer cell line A2780 and v) cancer cells from malignant fluids. The cationic polymer ExGen was taken as a carrier for transfection, while FITC-ON uptake was evaluated by flow cytometry. We found marked differences between these cell types. Cancer cells from the cell line A2780 and from patients showed a distinctly enhanced uptake compared to hematopoietic progenitors and leukemic blasts. Since bone marrow toxicity substantially limits any conventional chemotherapeutic regimen, a better ON uptake in cancer cells compared to hematopoietic precursors might give an advantage for therapeutic approaches using e.g. ON-based chemosensitization.
Insights
Antisense oligonucleotides (ONs) show promise in cancer therapy. This study found cancer cells exhibit significantly higher uptake of ONs than normal hematopoietic cells, suggesting a potential therapeutic advantage for targeted cancer treatments.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- Antisense oligonucleotide (ON) technology is a developing area in cancer chemotherapy.
- A key challenge is understanding the cellular uptake of ONs in both normal and malignant cells.
Purpose of the Study:
- To investigate the cellular uptake of antisense oligonucleotides (ONs) in various human cell types, including cancer cells and hematopoietic progenitors.
- To compare ON uptake efficiency between different cell lines and primary patient samples.
Main Methods:
- Utilized FITC-labeled phosphorothioate modified ONs for cellular uptake studies.
- Employed the cationic polymer ExGen as a transfection carrier.
- Quantified ON uptake using flow cytometry analysis.
Main Results:
- Demonstrated significant differences in cellular uptake across various cell types.
- Observed markedly enhanced ON uptake in the ovarian cancer cell line A2780 and patient-derived cancer cells compared to hematopoietic progenitors and leukemic blasts.
- Highlighted differential uptake between normal and malignant cells.
Conclusions:
- Enhanced cellular uptake of ONs in cancer cells compared to normal hematopoietic precursors offers a potential therapeutic advantage.
- This finding supports the development of ON-based chemosensitization strategies with potentially reduced bone marrow toxicity.
